CORRESPONDENCE

Rapid Phospholipid Turnover after Surfactant Nebulization in Severe COVID-19 Infection: A Randomized Clinical Trial

To the Editor:

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus targets the ACE-2 receptor on type II alveolar epithelial (ATII) cells. ATII cells synthesize and secrete lung surfactant, and surfactant deficiency consequent of ATII cell dysfunction may contribute to progression to acute respiratory distress syndrome (ARDS) in coronavirus disease (COVID-19), but this has yet to be confirmed (1). Several clinical trials of surfactant for COVID-19 ARDS are ongoing, but there is a critical need to optimize dose concentration, dose frequency and duration, and mode of delivery of therapeutic surfactant administration. In this pilot study, we evaluated the effectiveness of a prototype breath-synchronized vibrating mesh nebulizer to deliver exogenous surfactant to patients ventilated for severe COVID-19 infection (2, 3) and report here endogenous surfactant status, turnover, and half-life of administered surfactant. These results have not been previously reported in abstract form.

Methods

Patients ($n = 10$) were recruited within 24 hours of endotracheal intubation into a randomized control trial of nebulized surfactant in patients with COVID-19 ARDS (Clinical Trials number: NCT04362059) and were randomized 3:2 for surfactant and control arms. Results were compared with historic healthy control data (4). Surfactant was nebulized by an investigational vibrating mesh breath-actuated aerosol system (Aerogen Pharma), controlled by a flow sensor in the inspiratory limb of the ventilation circuit (3). Six patients were randomly allocated to receive three doses of 1,080 mg of Alveofact, a bovine surfactant widely used in preterm neonates (5), at $T = 0$, 8, and 24 hours. Tracheal aspirates were taken at 0, 8, 16, 24, 48, and 72 hours. Phospholipids were analyzed by electrospray ionization mass spectrometry (6). Results are presented as medians and interquartile ranges, with statistical significance determined by the Mann-Whitney test.

Results

Phospholipid analysis of baseline tracheal aspirates indicated that pulmonary surfactant was significantly compromised in patients ventilated for COVID-19 infection, with dipalmitoylphosphatidylcholine, the major surface-active component, being considerably reduced for all 10 patients (25.0, 20.9–29.4%)

compared with healthy volunteers (46.8, 39.0–49.4% total phosphatidylcholine; $P < 0.001$) (data recalculated from reference [4]). Although phospholipid compositions were identical between COVID-19 control and surfactant groups at baseline (Table 1), initial concentrations of total phosphatidylcholine and phosphatidylglycerol, typically enriched in surfactant, were significantly lower than in Alveofact and healthy control groups (4) with corresponding increased concentrations of phospholipids characteristic of cell membranes such as phosphatidylserine and sphingomyelin (SM). The significant elevation of SM in tracheal aspirates from patients at $T = 0$ hours compared with Alveofact (10.5, 8.2–12.1, vs. 1.2, 1.0–1.3%; $P < 0.01$) provided a basis for calculation of exogenous surfactant turnover. Importantly for turnover calculations, sphingomyelin fractional concentration remained relatively constant over the study period in the control group (Table 1). By contrast, aspirate phospholipid composition after surfactant nebulization changed substantially to resemble that of Alveofact. Phosphatidylcholine concentration doubled from 39.8% to 79% at $T = 8$ hours, phosphatidylglycerol increased from 3.1 to 13.9% at $T = 16$ hours, and all other phospholipid classes substantially declined. These changes gradually reversed with time, such that by 72 hours, phosphatidylcholine concentration was 59.4%, phosphatidylserine was 9.1%, and SM was 5.3%, reflecting decreased concentration of exogenous surfactant. The wide variation of absolute aspirate phospholipid concentration owing to variable recovery precluded its use for turnover calculation. Instead, exogenous surfactant turnover was determined relative to that of endogenous lipid in tracheal aspirates, based on the assumption that concentration and composition of endogenous lipid did not change substantially over the 72-hour study period. Alveofact turnover was calculated from the reciprocal of the percentage concentration of palmitoylsphingomyelin (SM16:0) as a marker of endogenous lipid. This value was maximal for all patients between $T = 8$ and $T = 16$ hours and returned toward baseline values by $T = 72$ hours (Figure 1, solid circles). Kinetic models of these data were constructed by superimposing three first-order exponential decay curves at $T = 0$, $T = 8$, and $T = 24$ hours (Figure 1, solid squares), assuming equal amounts of Alveofact were delivered at each nebulization, with good agreement between measured and modeled values. The model indicated the median estimated half-life for Alveofact phospholipid was 7.6 hours (range, 1.8–20.8 h) in these six surfactant-treated patients.

Discussion

This is the first study to evaluate exogenous surfactant pharmacokinetics in patients with COVID-19; the rapid turnover of administered surfactant has direct implications for design of surfactant therapy trials in both patients with COVID-19 and those with other ARDS. It may help clarify why the transient improved oxygenation in most adult ARDS studies after surfactant supplementation was not sustained (7). Our findings support the hypothesis that pulmonary surfactant deficiency may play an important role in patients mechanically ventilated for severe COVID-19. This is the first detailed analysis of phospholipid compositional changes after administration of a therapeutic dose of exogenous surfactant to any patient group; it sampled tracheal aspirates instead of BAL to minimize health care–associated infections and prevent patient desaturation during frequent bronchoscopy. The novel methodology to estimate turnover based on

Table 1. Concentration of Selected Phospholipid Classes in Tracheal Aspirate Samples over the 72-Hour Study Period for Control and Surfactant-treated Patients

	Phosphatidylcholine (%)	Phosphatidylglycerol (%)	Phosphatidylserine (%)	Sphingomyelin (%)
Alveofact composition ($n = 4$)	80.4 (8.0–81.2)	10.8 (8.5–11.4)	0.8 (0.4–4.3)	1.2 (1.0–1.3)
Control group ($n = 4$)				
0 h	48.0 (32.1–56.8)	2.2 (1.2–3.9)	22.6 (17.0–30.6)	9.8 (7.9–11.8)
8 h	48.5 (29.5–60.2)	4.2 (3.3–6.7)	18.0 (10.9–24.7)	9.1 (8.6–13.7)
16 h	38.0 (27.8–53.6)	2.7 (1.8–3.2)	17.3 (16.7–24.9)	9.0 (7.9–12.5)
24 h	34.1 (17.1–56.7)	3.5 (2.5–4.7)	20.5 (14.8–34.0)	10.4 (8.4–11.7)
48 h	38.7 (20.2–513)	3.3 (1.5–6.0)	27.0 (16.4–44.0)	10.9 (7.8–13.9)
72 h	35.4 (26.2–49.3)	2.1 (1.3–4.3)	32.4 (24.4–33.9)	11.8 (7.1–15.8)
Surfactant-treated group ($n = 6$)				
0 h	39.8 (29.8–52.3)	3.1 (2.2–4.8)	23.5 (11.2–25.9)	10.9 (8.2–13.0)
8 h	79.0 (75.4–84.8)	11.7 (8.0–13.9)	1.2 (0.9–1.9)	2.0 (1.3–2.4)
16 h	76.4 (68.3–79.1)	13.9 (8.0–16.1)	1.1 (0.8–2.2)	1.9 (1.2–2.7)
24 h	75.9 (61.3–79.4)	11.9 (8.0–13.3)	1.5 (1.3–8.6)	3.0 (2.1–4.6)
48 h	67.8 (54.5–73.4)	10.1 (8.2–11.2)	7.0 (2.5–12.2)	3.7 (2.5–5.1)
72 h	59.4 (44.2–68.9)	9.8 (5.0–11.8)	9.7 (5.4–21.6)	5.3 (4.6–7.2)

Data are presented as median (interquartile range).

Figure 1. Alveofact turnover in tracheal aspirate samples. An index of exogenous surfactant was calculated as the reciprocal of the percentage concentration of palmitoylsphingomeyelin (SM16:0), the predominant sphingomyelin species that was taken as a marker of endogenous phospholipid. The solid circles represent the measured data, whereas the solid squares are the modeled data generated by fitting an iterative kinetic model of three sequential exponential decay curves (mean ± SEM).

the different lipid profiles of Alveofact and tracheal aspirates was analogous to the lecithin to sphingomyelin ratio (8) and rested on the assumption that endogenous phospholipid concentration was constant over 72 hours in the treatment group but was diluted by exogenous surfactant. Importantly, although the index of surfactant turnover was not a direct measure of exogenous surfactant concentration, as the upper value is set by the concentration of SM16:0 in Alveofact, it enabled iterative kinetic modeling to estimate half-life from three first-order exponential decay curves superimposed at T = 0, T = 8, and T = 24 hours. The resultant modeling of the Alveofact index was a reasonable fit to the measured data (Figure 1) and indicated a rapid turnover of

exogenous surfactant in the airways and presumably the alveolus, such that little material remained at T = 72 hours. This data will be correlated with clinical variables in a future substantive report. This conclusion broadly agrees with the one other report of surfactant kinetics in patients with ARDS, which followed the loss of surfactant labeled with a tracer amount of ^{13}C-palmitate in dipalmitoylphosphatidylcholine (9). This rapid turnover of exogenous surfactant may be one contributor to the failure of clinical trials of surfactant therapy in ARDS, in addition to the heterogeneity of the patient population and multiple initiating factors. Our results suggest that more individualized and prolonged surfactant administration may be required to give time for recovery of the lungs in severe COVID-19. ∎

Anthony D. Postle, Ph.D.*
University of Southampton
Southampton, United Kingdom
and
University Hospital Southampton National Health System Foundation Trust
Southampton, United Kingdom

Howard W. Clark, M.A., D.M., D.Phil.
University College London Hospital
London, United Kingdom
and
University College London Hospital Biomedical Research Centre
London, United Kingdom

Jim Fink, Ph.D.
Aerogen Pharma Corporation
San Mateo, California

Jens Madsen, Ph.D.
University College London
London, United Kingdom

CORRESPONDENCE

Grielof Koster, Ph.D.
Madhuriben Panchal, B.Sc.
University Hospital Southampton National Health System Foundation Trust
Southampton, United Kingdom

Ratko Djukanovic, M.D., D.M., F.R.C.P.
University of Southampton
Southampton, United Kingdom
and
University Hospital Southampton National Health System Foundation Trust
Southampton, United Kingdom

David Brealey, M.B. B.S, Ph.D.
University College Hospitals London
London, United Kingdom

Michael P. W. Grocott, M.D.
University of Southampton
Southampton, United Kingdom
and
University Hospital Southampton National Health System Foundation Trust
Southampton, United Kingdom

Ahilanandan Dushianthan, M.B. B.S., Ph.D.
University Hospital Southampton National Health System Foundation Trust
Southampton, United Kingdom

ORCID IDs: 0000-0001-7361-0756 (A.D.P.); 0000-0001-7354-2028
(H.W.C.); 0000-0001-6527-2363 (J.F.); 0000-0002-1761-969X (G.K.);
0000-0001-6039-5612 (R.D.); 0000-0002-1982-3379 (D.B.);
0000-0002-9484-7581 (M.P.W.G.); 0000-0002-0165-3359 (A.D.).

*Corresponding author (e-mail: adp@soton.ac.uk).

References

1. Mason RJ. Thoughts on the alveolar phase of COVID-19. *Am J Physiol Lung Cell Mol Physiol* 2020;319:L115–L120.
2. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventós AA, *et al.*; Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. *N Engl J Med* 1996;334:1417–1421.
3. DiBlasi RM, Kajimoto M, Poli JA, Deutsch G, Pfeiffer J, Zimmerman J, *et al.* Breath-synchronized nebulized surfactant in a porcine model of acute respiratory distress syndrome. *Crit Care Explor* 2021;3:e0338.
4. Dushianthan A, Goss V, Cusack R, Grocott MP, Postle AD. Phospholipid composition and kinetics in different endobronchial fractions from healthy volunteers. *BMC Pulm Med* 2014;14:10.
5. Griese M, Dietrich P, Reinhardt D. Pharmacokinetics of bovine surfactant in neonatal respiratory distress syndrome. *Am J Respir Crit Care Med* 1995;152:1050–1054.
6. Madsen J, Panchal MH, Mackay RA, Echaide M, Koster G, Aquino G, *et al.* Metabolism of a synthetic compared with a natural therapeutic pulmonary surfactant in adult mice. *J Lipid Res* 2018;59: 1880–1892.
7. Meng H, Sun Y, Lu J, Fu S, Meng Z, Scott M, *et al.* Exogenous surfactant may improve oxygenation but not mortality in adult patients with acute lung injury/acute respiratory distress syndrome: a meta-analysis of 9 clinical trials. *J Cardiothorac Vasc Anesth* 2012;26:849–856.
8. Roux JF, Nakamura J, Brown E, Sweet AY, Gluck L. The lecithin-sphingomyelin ratio of amniotic fluid: an index of fetal lung maturity? *Pediatrics* 1972;49:464–467.
9. Cogo PE, Toffolo GM, Ori C, Vianello A, Chierici M, Gucciardi A, *et al.* Surfactant disaturated-phosphatidylcholine kinetics in acute respiratory distress syndrome by stable isotopes and a two compartment model. *Respir Res* 2007;8:13.

Prospective Identification of Subclinical Interstitial Lung Disease in a Rheumatoid Arthritis Cohort Is Associated with the *MUC5B* Promoter Variant

To the Editor:

Interstitial lung disease (ILD) is common among patients with rheumatoid arthritis (RA), but ILD is often diagnosed late when there is already a heavy burden of lung disease (1). Among patients with RA without a known history of ILD, it is estimated that approximately one-third of patients have high-resolution computed tomography (HRCT) abnormalities suggestive of ILD (subclinical ILD) and more than half of these patients demonstrated radiologic progression (2). These estimates of disease are likely biased owing to small sample size and/or retrospective study design (2–5).

Recently, we discovered that the *MUC5B* promoter variant is a genetic risk factor for patients with established RA-ILD (6). Given this association, we hypothesized that the *MUC5B* promoter variant would also be associated with subclinical ILD among patients with RA. We performed a prospective study of subjects with RA without known ILD to determine the prevalence of and risk factors for subclinical ILD in RA.

Methods

Subjects with RA (2010 American College of Rheumatology criteria and/or a clinical diagnosis of RA by a board-certified rheumatologist) were identified from the outpatient rheumatology clinic at the University of Colorado and asked to participate if they had no clinical diagnosis of ILD. The institutional review board approved all protocols (COMIRB 16-1907), and all patients provided written informed consent.

All subjects filled out questionnaires, had blood samples collected, had measurements taken of lung function with spirometry (FVC) and $D_{L_{CO}}$, and had lung imaging performed with HRCT scans.

All HRCT scans were read independently by two chest radiologists using a scoring form. Qualitative findings of interstitial fibrosis were defined by the presence of irregular reticular opacities, traction bronchiectasis, and/or honeycombing. Discrepancies were resolved by consensus. Subclinical ILD was defined as subjects with RA without a diagnosis of ILD at the time of enrollment and who had interstitial fibrosis on a prospectively performed HRCT as determined by radiologist consensus.